Aller au contenu principal
Accès ouvert déclaré 2026 review

Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis

2Citations signalées — pas une note de qualité
10Institutions déclarées
5Pays d’affiliation déclarés

Résumé fourni par la source

The aim of this study is to evaluate the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on haemoglobin (Hb) and haematocrit (Hct) levels in patients with heart failure (HF). We systematically searched PubMed, Web of Science, Cochrane Library, and Embase for randomized controlled trials (RCTs) until April 2025. Changes in Hb and Hct were evaluated in HF patients treated with SGLT2 inhibitors compared to control subjects. A random-effects model was applied to calculate mean differences (MDs) with corresponding 95% confidence intervals (CIs). Subgroup analyses were performed across different SGLT2 inhibitors, follow-up durations, and types of control groups. Between-study heterogeneity was quantified using the I2 statistic, and meta-regression analyses were performed to explore the influence of baseline clinical characteristics on haematologic responses. Publication bias was evaluated using funnel plots and Egger's test. Seventeen randomized controlled trials (RCTs) with 16 784 participants (mean age 68.65 years, 65.56% male) were included. Sodium-glucose cotransporter-2 inhibitors significantly increased Hb (MD = 0.68 g/dl, 95% CI: 0.53; 0.83, I2 = 39.7%, P-value <.0001) and Hct (MD = 2.15%, 95% CI: 1.73; 2.57, I2 = 66.6%, P-value < .0001) compared with controls. Subgroup analyses showed consistent benefits across individual SGLT2 inhibitors, duration of follow-up (≥6 months vs <6 months), and comparator type (placebo vs active control). There was no evidence of publication bias. Sodium-glucose cotransporter-2 inhibitors significantly increase levels of Hb and Hct in patients with HF. Further research is warranted to assess clinical significance in relation to Hb and Hct changes in patients with pre-existing anaemia or renal dysfunction.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis
Date Crossref
19/01/2026
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Diabetes Treatment and ManagementHeart Failure Treatment and ManagementErythropoietin and Anemia Treatment

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.